News AZ's Alexion extends gMG options with two Klygefa approvals AstraZeneca's Alexion unit has won approval in the US and EU for Klygefa, billed as a future blockbuster, for generalised myasthenia gravis (gMG).
News Rapid DEA review clears way for Takeda's narcolepsy launch Takeda has started to roll out its new narcolepsy therapy in the US, with competitive pricing to Jazz Pharma's current market leader Xywav.
News NHS use of Incyte's anal cancer drug Zynyz backed by NICE Hundreds of patients in England and Wales with anal cancer could soon be eligible for treatment with Incyte's cancer immunotherapy Zynyz.
News Lilly beats Novo to China with an oral GLP-1 for obesity Lilly's orforglipron has been approved in China, becoming the first oral GLP-1 agonist to enter the Chinese weight management market.
News Merck's rare tumour drug Pimjetmi claims FDA approval Merck's Pimjetmi has been cleared in the US for tenosynovial giant cell tumour, adding a third FDA-approved treatment for the rare disorder.
News Bayer bags FDA green light for stroke drug Sunharbo Bayer gets FDA nod for first-in-class oral Factor XIa inhibitor Sunharbo, a potential blockbuster, for secondary stroke prevention.
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.